Rift Valley Fever Innovation Lab: Rift Valley fever vaccine animal testing data at Sante Animale MCI in Mohammedia, Morocco

The objective of this study was to evaluate the safety and immunogenicity of a live, attenuated recombinant RVF arMP-12ΔNSm21/384 nucleotide deletion vaccine candidate in domestic ruminants. . The immunogenicity of 2 doses of 104 and 105 Tissue Culture Infectious Doses50% (TCID50) of the vaccine was assessed in of 2 groups of 10 sheep, 2 groups of 10 goats, and doses of 105 and 106 TCID50 were used to vaccinate 2 groups of 10 calves. The results showed that the immunogenicity among sheep, goats and cattle indicated that doses of 104 - 106 TCID50 elicited detectable antibody by day 7 post-vaccination and antibody titers that ranged from 1:14 to 1:305 on day 14 PV with sustained titers through day 28 PV. Overall, these findings indicated that the RVF arMP-12ΔNSm21/384 vaccine is a promising candidate for the prevention of RVF among domestic ruminants.

Querying over HTTP

Splitgraph serves as an HTTP API that lets you run SQL queries directly on this data to power Web applications. For example:

curl https://data.splitgraph.com/sql/query/ddn \
    -H "Content-Type: application/json" \
    -d@-<<EOF
{"sql": "
    SELECT *
    FROM \"usaid-gov/rift-valley-fever-innovation-lab-rift-valley-fever-fc4b-6abn\".\"rift_valley_fever_innovation_lab_rift_valley_fever\"
    LIMIT 100 
"}
EOF

See the Splitgraph documentation for more information.